Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 1995  |  Volume : 16  |  Issue : 4  |  Page : 219-224

Phase II trial of paclitaxel in cases of advanced ovarian carcinoma and other malignancies.

Medical Oncology Department, Tata Memorial Hospital, Bombay, India

Correspondence Address:
BS Parikh
Medical Oncology Department, Tata Memorial Hospital, Bombay, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Paclitaxel is a new anti-tumour agent. The drug hs been found useful in advanced ovarian malignancies and various other malignancies. Phase II trial of this drug was conducted at Tata Memorial Hospital to study efficacy, safety and toxicity profile of this drug. The response rate was 18 percent for advanced ovarian carcinoma and partial response was seen in one case of choriocarcinoma. Acceptable degree of myelosuppression and alopecia were seen as side effect. No hypersensitivity reactions were noticed. We conclude that Paclitaxel is a reasonably safe drug with good efficacy in various malignancies.

[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal